Global Herpes Treatment Market expected to reach USD 1.87 billion by 2033 with 4.28% CAGR

From GlobeNewswire.: 2024-07-05 21:00:00

The Global Herpes Treatment Market is expected to grow from USD 1.23 Billion in 2023 to USD 1.87 Billion by 2033, with a Compound Annual Growth Rate (CAGR) of 4.28%. Antiviral drugs like famciclovir and acyclovir are commonly used. However, high costs can limit access to essential medications, affecting market growth.

The varicella-zoster virus (VZV) segment is projected to dominate the herpes treatment market due to increasing prevalence and the development of new drugs. Prescription drugs, administered under medical supervision, are expected to grow the fastest, with acyclovir and valacyclovir leading the way.

In terms of route of administration, the oral segment is anticipated to see the highest growth, driven by awareness campaigns and the psychosocial impact of outbreaks. North America is expected to hold the largest market share, with the United States playing a significant role in shaping the industry’s direction.

Europe is forecasted to have the fastest growth in the global herpes treatment market, driven by the development of cost-effective therapeutics. Competitively, key players like Pfizer and GSK are working on strategic initiatives to increase market share. Recent collaborations like Gilead Sciences and Assembly Biosciences aim to develop antiviral therapies.

In-depth analysis by Spherical Insights shows segmentation based on virus type, drug type, and region, offering a comprehensive view of the global herpes treatment market. Key players in the industry include Zydus Pharmaceuticals, Teva Pharmaceutical Industries, Sun Pharmaceutical Industries, and others. Major regions include North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.



Read more at GlobeNewswire.: Global Herpes Treatment Market Size To Worth USD 1.87